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Abstract: The major objectives of an efficient dairy farm operation include a successful lactation period, high milk yield relative to
the feed costs, reproductive competence, and finally the returning of the cow to the body condition score (BCS) that existed before
lactation so she will be prepared for another lactation. In cows a milk yield response to bovine somatotropin (bST) treatments at 60
d after parturition has been well studied and fully documented. Milk production response to bST occurs because of its known effects
on partitioning of nutrients and because a greater proportion of the nutrient intake is used for milk synthesis. It increases liver
glucose output, cardiac output, blood flow to the mammary gland and uptake of nutrients used for milk synthesis by the mammary
gland among other effects. In addition, ST decreases the rate of oxidation of amino acid and glucose and therefore decreases glucose
clearance. Treatment with bST results in coordinated changes of various organs and tissues that naturally occur during the transition
from a nonlactating to lactating state when circulating concentration of ST is high. Because of the known effects of bST described
above, use of bST during the transition period may cause positive and beneficial effects supporting milk synthesis prior to parturition.
This review recaps the diverse physiological effects of ST on lactation, discusses the major mechanisms that mediate these effects,
and summarizes the recent studies using bST during the transition period to increase milk production in cows.
Key Words: Somatotropin, lactation, transition period, metabolism, dairy cow.

Geçifl Dönemi ‹neklerde Bovine Somatotropin Kullan›m›
Özet: Süt üreticilerinin en önemli amaçlar› baflar›l› bir laktasyon dönemi, yem maliyetine oranla daha yüksek süt üretimi, do¤um
sonras› hayvanlar›n tekrar gebe b›rak›lmas› ve en son olarak da hayvanlar›n do¤um sonras› sahip olduklar› kilolara tekrar
ulaflt›r›lmas›d›r. Bovine smatotropin (bST) kullan›ld›¤›nda süt verimindeki art›fl›n nedeni, besinlerin vücut da¤›l›m›na olan etkisi ile
al›nan besinlerin büyük bir bölümünün süt sentezlenmesi için yönlendirmifl olmas›d›r. bST bir çok etkisinin yan› s›ra ayr›ca
karaci¤erden glikoz sal›verilmesini, toplam kalp hacmini, meme bezine gelen kan miktar›n› ve süt üretimi için gerekli olan besin
al›m›n› art›r›r. Bunlara ilaveten, bST amino asit ve glikozun oksidasyonunu ve böylece glikoz kullan›m›n› da azalt›r. bST
kullan›ld›¤›nda birçok doku ve organda koordineli olarak de›iflikli¤e sebep olur. Bu de¤ifliklikler geçifl döneminde kandaki ST’nin
yüksek oldu¤unda görülen de¤ifliklikler ile benzerdir. bST’nin yukar›da da bahsedilen etkilerinden dolay›, geçifl döneminde
kullan›lmas› süt üretiminin art›r›lmas› aç›s›ndan olumlu ve yararl› olabilir. Bu derleme kapsam›nda, ST’nin yararl› etkileri ve ana
mekanizmalar› tart›fl›larak geçifl döneminde bST kullan›m› ile süt üretimine etkisi üzerine yap›lan yeni araflt›rmalar hakk›nda bilgi
verilmesi amaçlanm›flt›r.
Anahtar Sözcükler: Somatotropin, laktasyon, geçifl dönemi, metabolizma, süt ine¤i

Introduction
As early as the 1930s, the growth-promoting effects
of somatotropin (ST) were characterized. Evans and
Simpson (1) showed that crude extracts of bovine
pituitary increased the growth rate of rats. In 1937, two
Russian scientists, Asimov and Krouze (2), performed the
first bST research, using 600 lactating dairy cows. These
researchers found that injecting cows with extracts of the
pituitaries of slaughtered cows resulted in increased milk

production. Research continued during and after World
War II as scientists sought an effective means of
increasing food production. However, the amount of ST
from each pituitary was so low that this source would not
be practical for improving total milk production (3).
The arrival of modern technology enabled the
development of recombinant bovine somatotrophin
(rbST), which provided an unlimited source of ST for
research and, potentially, for commercial application. This
571
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allowed researchers to conduct many studies using
recombinant bST. From these studies it was concluded
that exogenous ST could increase milk production of dairy
cows at least 10% to 15%. Obtaining a milk yield
response to bST did not require special diets or different
feed ingredients. However, treated cows did need
adequate amounts of balanced diet that contains all
nutrients necessary for supporting expected milk
production (4).
Treatment of cows with bST during lactation was
approved for use in the US in 1994. Since then it has
been used extensively. In addition, more than 34
countries have reached similar conclusions with respect to
food safety, and approved the use of bST, such as Algeria,
Brazil, Bulgaria, Columbia, Costa Rica, Czech Republic,
Honduras, Hungary, Jamaica, Kenya, Korea, Malaysia,
Mexico, Namibia, Pakistan, Peru, Romania, Russia,
Slovakia, South Africa, Turkey, United Arab Emirates,
Ukraine and Zimbabwe.
Bovine somatotropin had been given to 335,000
cows in New York (45% of the state total), the major
dairy state in the eastern US, after over a year period.
About 55% of all sales of bST have been to farmers who
have 100 or fewer cows (5). In 1998, of nearly 9 million
dairy cows in the US, about 25% were in bST treated
herds, and 300 additional dairy farmers were reported to
be adopting use of bST per month. The average dairy
farmer used the commercial bST product (POSILAC®) to
supplement more than 50% of the herd depending upon
individual herd management practices and stage of the
adoption.

Responses to somatotropin supplementation
Somatotropin is a major regulator of growth in
mammals. In the liver ST regulates the expression of a
wide range of proteins including hormone receptors and
growth factors, secretory products, and enzymes such as
cytochrome P450 (6). Somatotropin also has a unique
effect on stimulating mammary gland development (7)
and lactation (8).
Typical milk yield (MY) response to bST is an increase
of at least 10-15%. However, the response can be much
greater with better care and management of the cows
(9,10). After the first few days of bST treatment, MY
increases gradually and reaches a peak and the increase is
maintained with continuous injections of bST. Milk yield
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gradually returns to normal pre-injection levels after
cessation of treatment (11).
Obtaining a MY response to bST does not require
special diets or different feed ingredients. Substantial MY
responses have been observed on diets ranging from
pasture to the more typical total mixed ration (TMR)
diets. However, dry matter intake (DMI) increases in bST
treated cows after a few weeks of the supplementation
and persists throughout the interval of bST use. Thus,
treated cows require adequate amounts of a balanced diet
rather than a special diet (10).
a) Effects of bST on the Mammary Gland
In early studies concerning the actions of ST, it was
concluded that a direct effect of ST on mammary gland
development was unlikely. Studies failed to detect an ST
receptor on the mammary epithelial cell of the cow (12).
Moreover, infusions of ST directly into mammary artery
of sheep did not stimulate milk production (13).
However, in rodents, a direct effect of ST on mammary
development and function was established (14,15).
Although most evidence suggested an indirect effect of ST
on mammary gland development in ruminants, it was
found that ruminants also expressed mRNA for the ST
receptor in mammary gland (16). Furthermore,
immunologic staining of ST receptors in mammary tissue
of pregnant and lactating cows was also reported (17).
Collier et al. (18) observed a significant effect of ST on
mammary growth of pregnant heifers when it was
administered through the teat canal. However, as
indicated, unilateral close arterial infusion of ST into onehalf of the mammary gland of sheep did not increase milk
yield performance compared with the uninjected half
(13). Furthermore, ST administration through the teat
canal of lactating goats did not result in increased milk
production response (19). This latter response would not
be expected unless there was uptake of ST across the
apical membrane of the epithelial cells or uptake into the
general circulation and subsequent action in mammary
gland.
The acute rise in MY in response to bST and rapid
decline after stopping bST injection argues against cell
proliferation being caused by ST in the short-term.
Knight et al. (20) observed that ST treatment did not
affect the amount of mammary parenchyma and BrdUlabeling of mammary epithelial cells in vivo during the
first 6 wk of lactation. On the other hand, a large
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increase in parenchymal volume was observed in midlactation goats treated over a 22 wk period with
exogenous ST (21). Other studies with cows and goats
reported trends and/or significant increases in key
enzymes in the mammary gland (such as acetyl CoA
carboxylase, acetyl CoA synthetase and fatty acid
synthetase) due to bST supplementation. Thus, bST
directly and/or indirectly causes an increase in the rates of
milk synthesis per cell and improved maintenance of
secretory cells (22,23).
Somatotropin shows one of its effects on mammary
gland function indirectly via the action of insulin like
growth factor-I (IGF-I) on the tissue (24).
Concentrations and actions of IGF-I are likely the most
important link to tissue response with higher
concentrations of ST. Somatotropin has a major role in
regulating the concentrations of IGFs that are in the
circulation. Concentrations of IGF-I increase during bST
treatments because of both induced release of IGF-I from
a hepatic storage pool and greater biosynthesis of IGF-I.
Biosynthesis is regulated by increased mRNA levels and
mRNA stability (25). Increase in IGF-I concentration was
maintained with continued injections of ST and the
increase in MY was parallel to the increase in IGF-I.
Cessation of ST supplementation caused a parallel
decrease in both MY and blood concentrations of IGF-I
(25).
Insulin like growth factor-I has both autocrine and
paracrine actions in addition to its endocrine actions (26).
At the cellular level, IGF-I locally stimulates amino acid
transport, synthesis of RNA and DNA, and synthesis of
cellular proteins (27). Receptors for IGF-I were
demonstrated in mammary tissue and IGF-I is a local
mediator of mammary epithelial growth and development
(28). Intralobular stromal cells, small blood vessels, and
capillaries contain IGF-I receptors in the mammary gland
(29). During ST treatments, IGF-I binds in the cytoplasm
and the stroma of epithelial cells. Insulin like growth
factor-I stimulates the cellular activity of mammary gland,
it increases synthesis of RNA and DNA, and the synthesis
of cellular proteins. Therefore, it is a local mediator of
mammary epithelial growth and development (27).
Interestingly, close arterial infusions of IGF-I into
mammary gland of goat, but not systemic infusions of
IGF-I, increased MY dramatically (30). However,
lactational response to close arterial infusion of IGF-I was
much less than that of systematic bST treatments which

suggests that the mechanism of action of bST with regard
to stimulatory effects on MY cannot be limited only to the
known effects of IGF-I.
b) Effects of Somatotropin on Other Tissues
Somatotropin exerts many different effects on protein
metabolism in both mammary and non-mammary tissues.
Bovine somatotropin increases MY with no change in milk
composition, unless there is energy deficiency. It
provokes MY increase by increasing overall blood supply
to mammary gland (water uptake), altering glucose
metabolism (lactose synthesis in the mammary gland),
enhancing lipolysis and increasing lipogenesis in the
mammary gland (supply of lipid precurcors), and also
modifying protein metabolism (supply of amino acids). As
a result, milk yield increases and the composition of milk
does not change from normal (31).
Increased MY response due to ST results mainly from
altered partitioning of nutrients in favor of mammary
glands and from an increase in the synthesizing capacity
and/or longevity of the milk synthesizing cells (22).
Somatotropin is a primary homeorhetic regulator during
pregnancy and lactation; it regulates partitioning of
nutrients (carbohydrates, lipids, proteins, and minerals)
and plays an important role in the coordination of various
organs and tissues (4). To support milk synthesis, the
metabolism of other tissues is stimulated to provide the
necessary precursors.

Carbohydrate metabolism
During early lactation, glucose is used almost
exclusively by the mammary glands (exceptions are
nervous system and brain), and MY is heavily dependent
upon increased glucose supply to the gland. If bST is to
increase MY, then it must act in a way to direct more
glucose to the mammary gland. This can occur through a
variety of individual actions of bST. First, bST increases
mammary blood flow so that more blood perfuses the
mammary gland and increased uptake of glucose can
occur (31). A decreased ability of insulin (INS) to inhibit
gluconeogenesis is observed following bST treatments.
Both in vivo (32) and in vitro (33) studies demonstrated
that hepatic rates of gluconeogenesis were increased
during treatment of dairy cows with bST. Furthermore,
ST decreased sensitivity of INS receptors to INS in the
peripheral tissues and this resulted in decreased overall
uptake of glucose in peripheral tissues. This minimized
the oxidation of glucose to CO2, and as a consequence
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more glucose was made available to the udder.
Somatotropin also stimulated increased feed intake, and
as a result, more propionate was produced in the reticulorumen and became available for gluconeogenesis (34). In
vitro studies of liver tissue of ST treated cows showed a
60% increase in capacity to use propionate for glucose
synthesis (33).
Pyruvate carboxylase (PC) and phosphoenolpyruvate
carboxykinase (PEPCK) are potential rate-limiting
enzymes for hepatic gluconeogenesis during the
transition period (35). It was speculated that exogenous
ST would increase mRNA synthesis in the liver that coded
for these enzymes (11). On the other hand, Pershing et
al. (36) concluded bST stimulation of milk production was
not mediated through enhanced liver gluconeogensis in
cows with 80 days in milk (DIM). Somatotropin also
increased lipid mobilization and more glycerol then was
available as a precursor for gluconeogenesis. To sum up,
the total of these actions would be that higher blood
glucose concentrations occurred and this glucose could be
directed to the mammary gland to support lactation. In
addition to increased glucose production in the liver,
glucose usage by other lean body tissues decreased.
Because glucose is used as a primary energy metabolite
and as a substrate for synthesizing milk constituents,
energy needed by other peripheral body tissues would be
derived from products of lipolysis or metabolism of nongluconeogenic compounds arising from the rumen and
lower digestive tract.

Lipid metabolism
Nutritional status plays a major role in the regulation
of lipid metabolism. Exogenous bST given to animals
alters both lipogenesis and lipolysis in adipose tissue with
the net effect being related to energy balance (EB) (11).
When cows are in positive EB, synthesis and deposition of
lipids in adipose tissue are reduced by ST, which, in turn,
increases the availability of nutrients and their utilization
for milk production (22). Insulin performs important
homeostatic control in the regulation of lipid metabolism.
Somatotropin reduces the ability of INS to stimulate
lipogenesis in adipose tissue. Thus, ST reduces the action
of INS, suppresses lipogenic enzyme activity, and reduces
glucose uptake (22). These coordinated changes in INS
actions would support production of glucose from
available precursors and conservation of glucose for
mammary use by shifting peripheral tissues to utilization
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of other substrates available, in large part, due to
combined actions of ST and INS.
When cows are in negative EB, ST stimulates lipolysis;
it alters the sensitivity of adipose tissue to β-adrenergic
agents (22). Therefore, for cows that are in negative EB
and are being treated with bST, increased lipid
mobilization would be a major source of energy needed
to support milk production (37). Lipolysis is regulated by
a signal transduction system that includes cAMP,
stimulatory G proteins (Gs) and inhibitory G proteins (Gi).
Catecholamines act through the Gs system to stimulate
lipolysis, whereas adenosine exerts its antilipolytic affects
via the Gi system. When adenosine binds to its receptor it
stimulates Gi which uncouples Gs protein activation of
adenyl cyclase catalyzed by catecholamines. This leads to
the inhibition of the lipolytic pathway that is stimulated by
catecholamines. Somatotropin alters lipolysis through an
increase in response to catecholamines with no change in
sensitivity. Epinephrine challenge following ST treatment
dramatically increased non-esterified fatty acid (NEFA)
concentrations in plasma. Interestingly, ST treatment
resulted in modest changes in β and α2 adrenergic
receptor numbers. However, the activity of Gi proteins
was reduced significantly by ST treatments. As a result, it
has been suggested that ST impaired the ability of Gi to
interact with adenyl cyclase. This, in turn, would increase
the effectiveness of Gs system stimulated by
catecholamines (11).
The events described above would dramatically
increase mobilization of lipids from the adipose tissue,
and increase blood NEFA and glycerol. Thus, there would
be greatly reduced fatty acid synthesis or no net
synthesis, and hence, less acetate and glycerol use in the
adipose tissue. Therefore, the net result would be a shift
in the availability of these metabolites in the mammary
gland where they can be used for synthesis of short and
medium chain-fatty acids that are themselves used for TG
synthesis and milk production. Therefore, lipolysis also
must be an important pathway to provide needed
precursors in the early postpartum period of cows
especially to supply the energy needed for milk
production (11).

Amino acid metabolism
Somatotropin treatment increases milk protein
synthesis in lactating cows via improved efficiency of
amino acid utilization. A reduction in circulating urea
nitrogen and in urinary nitrogen loss were reported
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following bST treatment (31). During negative energy
balance ST will spare protein use as a source of energy in
tissues because it increases lipid mobilization and
enhances glucose metabolism.
Proteins that are
mobilized from the muscles can be used in the liver, in the
gut, and in the blood and this will increase overall
metabolism and efficiency of protein use. Amino acids
mobilized have an important role in supporting growth of
some organs (liver, heart, digestive tract) rather than to
support milk synthesis (38). Amounts of amino acids that
are oxidized to provide energy will be reduced and the
protein mobilized can be used for growth of specific
tissues and milk protein synthesis. As indicated, ST causes
an increase in feed intake, which will make more
nutrients and amino acids available to increase MY, and
this will lessen the need for tissue mobilization processes.

Mammary blood flow
It has been established that nutrient supply to the
mammary gland is one of the major limitations for the
activity of secretory cells and milk synthesis. A lactating
mammary gland places a heavy demand on the animal to
provide substrates for milk synthesis (31). With bST
injections, along with the increases that occur in MY,
cardiac output also increases. Insulin like growth factor-I
has a role in the increased blood flow to the mammary
gland that appears to be mediated by production of nitric
oxide (30). Somatotropin also increases conversion of T4
to the tissue active thyroid hormone T3 specifically in the
mammary gland and the increase in T3 alters local
metabolism and helps mediating the galactopoietic
response (39). Thus, both increased milk secretion and
local metabolism drive more blood to mammary gland
and this, in turn, supplies greater quantities of water and
nutrients needed for milk synthesis.
bST during transition period
The approved time during the lactation cycle of cows
to start use of bST is at about peak MY (~60 ± 3 d) and
its use is continued throughout the remainder of the
lactation (40). Milk yield gradually increased over the first
few days following bST treatment and reached to
maximum concentration during the first week. Despite
large increases in milk production, feed intake did not
increase immediately following bST treatment. Early
production responses therefore, were due mostly to
partitioning of nutrients away from body tissues to
mammary gland use to support increased milk synthesis.

Although increased MY responses typically are found
when cows are injected with bST beyond 60 d
postpartum, no such increase in MY was observed when
exogenous bST was injected during prepartum and early
postpartum periods, which included the so-called
transition period. Bines and Hart (41) speculated that
because of delayed increase in DMI, treatment with bST
during the transition period might lead to acute animal
health problems such as ketosis, fatty livers, wasting, and
increased susceptibility to other diseases, or it could
result in lower than expected MY responses.
a) bST injections during prepartum period
Studies by Eppard et al. (42) failed to show an
increase in MY when they injected Holstein and Jersey
cows during the prepartum period with a full standard
dose of bST (POSILAC®). Simpson et al. (43)
administered growth hormone releasing factor (GRF)
prepartum to beef heifers to increase secretion of ST
before parturition and during early lactation. Treated
heifers lost more body weights (BW) and had delayed
ovarian activity, whereas no difference was observed in
MY. In another trial, Holstein cows received 0, 5 or 14
mg bST/d during the last 46 d before parturition (44).
Cows treated with 14 mg bST/d had increased yields of
solids-corrected milk (SCM) only during wk 1. However,
they found no differences in SCM among treatments.
Except for the cows treated with 5 mg/d of bST during
wk 10 of lactation, EB was negative for all cows during
the first 70 d of lactation. Bachman et al. (45) evaluated
whether a dose of 25 mg bST/ d administered prepartum
affected postpartum MY of Holstein cows. After
covariance adjustment for previous total lactation MY,
3.5% fat corrected milk (FCM) yields of treated and
control cows did not differ. They concluded that bST
treatments during prepartum period did not have either
a positive or a negative effect on MY during the following
lactation. None of the studies that used bST treatments
during the transition period have reported acute animal
health problems such as ketosis, fatty livers, wasting, and
increased susceptibility to diseases in the treated cows.
Stelwagen et al. (46) administered 20 or 40 mg bST
daily to Holstein heifers during the last trimester of the
first pregnancy. They found a significant increase in FCM
production of the heifers injected with 20 mg bST/d but
only after 90 d of lactation. Putnam et al. (47) reported
a significant effect of prepartum bST treatments on milk
production during early lactation which appeared to
575
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increase as lactation progressed. The exogenous bST
injections (500 mg over 14 d period) were initiated 28 d
prior to expected calving date and were continued until
parturition. Cows treated with bST in their trial produced
3.3 kg/d more milk than uninjected controls during the
first 42 d of lactation. However, cows in the bST treated
group had significantly higher initial body condition score
(BCS) than the controls when they were assigned to the
trial. This allowed treated cows to mobilize more body
reserves than controls and to lose more BCS without a
negative effect due to bST. This is a very important
factor because bST use likely increases negative energy
balance and greater loss of body weight, which supports
the greater milk production until the DMI increases.
b) bST injections during postpartum period
As reported for prepartum treatments, early
postpartum injections of bST also showed inconsistent
results. de Boer et al. (48) injected cows with 20.6 mg
bST/d starting postpartum 4-9 d. No significant
differences were detected for MY of control vs. bST
treated cows. Unfortunately, the cows assigned to bST
had lower MY potential based on the rate and extent of
decline in MY after cessation of bST injection. Thus, bST
injections enhanced MY to levels similar to those of
controls (48). Moallem et al. (49) studied the
mechanisms of how Ca soaps of fatty acids and bST affect
production and reproduction of high producing cows.
They injected 500 mg of bST every 14 d from 10 to 150
DIM. Milk yield during the first 60 d did not differ
between treatments.
However, bST treatment
significantly enhanced MY beyond 60 d and the peak milk
production increased for injected cows. On the other
hand, the effect of treatment on BCS was severe. The
BCS of injected cows decreased more and was
considerably less for treated cows and postpartum
conception rate was affected adversely compared to
uninjected cows. Santos et al. (50) investigated effects of
bST on the performance of early lactation cows fed diets
differing in ruminally degradable starch. Holstein cows
received biweekly injections of 500 mg bST for 90 d
starting at 5 DIM. A positive MY response was observed
during the first 45 d and for the total treatment period
(90 d). Interestingly, MY response to bST was less
between 7 and 13 wk than from 1 to 6 wk. Neither EB
nor BCS were determined in this study. Authors
concluded that the response to bST was less than usually
observed for cows when bST injections began at peak
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MY. In another study, the same dose of bST was injected
every 14 d from 10 to 150 DIM (51). They concluded
that bST injected early in lactation increased MY.
However, increase in MY occurred at the expense of an
extensive period of NEB and decrease in BW and BCS
despite an increase in DMI was observed due to bST
treatment.
Richard et al. (52) reported a 6% increase in MY
when cows were injected with 50 IU of bST starting
postpartum 20th d; milk fat also was elevated by 25%. In
the same trial, when cows were injected beginning on 0
d, MY response was greater (12%) with no change in
milk fat. Chalupa et al. (53) treated cows fed a diet that
contained 0% or 1.2% sodium bicarbonate with 50 IU
bST starting at 4th wk of lactation. They reported that
bST treatment increased MY by 4.7 kg over control cows
and there also was a 1.05 point increase in milk fat
percentage. Feed intake of injected cows tended to
increase (17.6 kg vs. 16.1, P < 0.11). In one of the
largest trials, Stanisiewski et al. (54) injected 5 mg or 14
mg bST/d from 14 d postpartum through 60 DIM. Cows
that received either 5 or 14 mg of bST/d produced more
FCM than controls, but FCM of the two bST treated
groups did not differ. However, cows receiving the lower
dose (5 mg/d) had higher pregnancy rate and higher
conception rate than all other experimental cows. Cows
receiving 5 mg bST/d also maintained BCS as uninjected
controls.
Variable results within and among trials that evaluated
use of bST either pre- or postpartum period may have
been due, in part, to differences among the doses, diets
the animals were fed, or due to differences in BW and
BCS of the animals. Usually, a high dose of bST increased
the length of time cows were in NEB; loss of BW and BCS
occurred even though an increase in DMI might have
occurred. Thus, adequate BCS (55) for cows injected with
bST pre- and/or postpartum is required because the cows
require good management and adequate nutrition to
produce and reproduce well.
c) bST injections during both prepartum and
postpartum periods
Treatment with a lower dose of bST during both
prepartum and postpartum periods has a potential to
cause metabolic changes after parturition that are
beneficial to the health and performance of the cows
(56). In one study, pre- and postpartum injections of
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15.3 mg bST/d showed increased concentrations of ST,
IGF-I and T3 in plasma (57). Evidence suggests that
changes in circulating concentrations of hormones,
growth factor and glucose can be beneficial. In the same
study, pre- and postpartum injections of bST increased
DMI of cows after parturition, and there was a smaller
decrease in BCS and BW. This allowed the cows to
recover to satisfactory BW and BCS more rapidly during
early lactation. Cows also produced quantitatively greater
daily MY and 3.5% FCM. Thus, the changes in
concentrations of metabolic hormones likely had a role in
the positive effects on DMI, BCS, BW and MY of these
cows.
Gulay et al. conducted two consecutive experiments
with bST during the transition period. During the first
experiment (58), injections of bST (10.2 mg bST/d)
began approximately 21 ± 3 d before expected calving
dates and biweekly injections of bST continued up to
postpartum 42nd d. No injections of bST were given
between postpartum 42nd d and d 100 ± 4 postpartum,
but all cows received full dose of POSILAC® beginning at
d 100 ± 4 postpartum. During the second experiment
(59) injections began approximately 21 d (± 3 d) before
expected calving dates and were continued up to d 42 (±
2 d) postpartum. After 60 d, all cows on experiment
received the full dose of POSILAC® biweekly (500 mg/14
d). Data from both the first and second studies suggest
that use of 10.2 mg bST/d during late prepartum and
early postpartum periods caused no apparent negative
effects on the treated cows. Although EB was measured
only in the second study (59) during first 4 wk of
postpartum, NEB was not greater in injected cows than in
uninjected cows in either study (58,59). This was an
indirect conclusion for the first study since the increase in
MY and BW and the changes in BCS were equal or better
in injected relative to in uninjected cows. Injection of bST
resulted in better recovery of BW and BCS during early
lactation, especially after injections were stopped around
d 42 postpartum (58). During the second study, low
dose of bST did not provoke a greater loss of BW or
decrease in BCS compared to untreated cows. Cows in
both groups appeared equally capable of replenishing
their body reserves even though all cows started injection
of a full dose bST around postpartum 60th d; a daily dose
was three times greater than that injected before d 42.
Bovine somatotropin treatments did not adversely or
positively affect the rate of increase in DMI during the

first 28 d of postpartum period; the increase in DMI was
same for both treated and untreated cows (59). In both
studies, bST treated cows produced more milk and 3.5%
FCM during the injection period. In the first study, no
carryover effects of bST were detected on MY as
evidenced by the fact that the increase in MY did not
persist after bST injections were stopped around d 42
postpartum (58). On the other hand, during the second
study, treated cows also produced more milk when all
cows (controls and treated) were injected with full dose
of bST (>60 d of lactation). They also had higher
concentrations of ST, INS and IGF-I prepartum and higher
ST and IGF-I postpartum (59). The findings of these
studies show that bST injection has general and likely
more diverse effects, which results in greater MY and
DMI without apparent negative effects. Indeed, results
indicated the overall effects of prepartum and early
postpartum bST were beneficial since BW and BCS were
better maintained and concentrations of metabolic
hormones were improved.

Summary and Conclusions
When injected during ongoing lactation, bST resulted
in an exceptional increase in milk production of dairy
cows. Because of its positive effects on blood glucose,
lipids and amino acid concentrations and blood
circulation, bST increases milk yield without affecting the
overall composition of the milk. This increase would be
equal to that normally achieved by AI and genetic
selection over 10-20 y period. Somatotropin also has a
pivotal role in homeorhetic control of metabolism and
nutrient partitioning (carbohydrates, lipids, proteins, and
minerals) of the cow during the transition period. The
transition period and the early lactation period were
considered as time periods that have the potential to
enhance lactational performance.
Increasing
concentrations of ST has a potential to augment the
metabolic changes that favor the mammary gland and
have a positive effect on DMI. In a broad view, bST
affects the system in a positive way and makes it possible
for cows to respond better later in lactation without
apparent negative effects on health. Changes in
concentrations of metabolic hormones, likely coupled
with effects on various organs, suggest strongly a
beneficial effect of bST during the transition period. This
can be interpreted that injections of bST may have a
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potential use during the postpartum period and probably
during the prepartum period, to improve metabolic status
and improve overall milk yields during early lactation.
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